GLP-1 is a satiety hormone produced in your small intestine in response to food
FDA Warning: RISK OF THYROID C-CELL TUMORS FDA Warning: RISK FOR ILEUS (INTESTINAL BLOCKAGE) (FDA 09/22/2023) References: Buckley ST et al (2018): Transcellular stomach absorption of a derivative glucagon-like peptide-1 receptor agonist
Targets skin and connective tissue regeneration
The potential for headaches may stem from various factors, including dehydration, blood flow changes, and individual sensitivity
Flynn McGuire, a physician at the University of Utah, went through the BPC-157 literature himself and turned up three small pilot studies totaling thirty participants, with no control groups and nothing that could answer safety or efficacy
Switching requires new titration (812 weeks), may temporarily restart GI side effects, and will need insurance reauthorization but the mechanism shift from dual to triple agonism may produce meaningful additional weight loss